ANTİHİPERLİPİDEMİKLER KAYNAKLI İLAÇ ETKİLEŞİMLERİNİN TESPİTİ: GÖZLEMSEL BİR ÇALIŞMA

Öz

Amaç: Bu çalışma antihiperlipidemikler kaynaklı ilaç-ilaç etkileşimlerini (DDI), DDIs tespit etmede kullanılan programlar aracılığıyla ortaya koymayı amaçlamaktadır. Gereç ve Yöntem: Kasım 2022 ile Nisan 2023 tarihleri arasında en az bir anti-hiperlipidemik ilaç ve farklı bir farmakolojik gruptan ilaç içeren 250 reçete, DDI açısından değerlendirildi. Değerlendirmeler, Van'daki bir serbest eczaneden alınan reçeteler üzerinden üç farklı DDI kontrol programı (RxMediaPharma®, Medscape ve Drugs.com) kullanılarak gerçekleştirildi. Sonuç ve Tartışma: Reçetelerin 115'inde anti-hiperlipidemik ilaçlara bağlı DDI'lar tespit edilmiştir. DDI'lar 38 aktif madde çifti arasında meydana gelmiştir. Etkileşimlerin %85'inin atorvastatinden kaynaklandığı belirlendi. En sık DDI, atorvastatin ve pantoprazol arasında bulunmuştur. 38 farklı madde çiftinden yalnızca 7'si için, üç program da etkileşim sonucunu vermiştir. Anti-hiperlipidemik ilaçlara bağlı DDI'ların genellikle orta düzeyde olduğu belirlenmiştir. Ancak, çalışmada kullanılan üç DDI kontrol programının DDI'ları tespit etmede farklı sonuçlar verdiği görülmüştür.

Anahtar Kelimeler

• Antihiperlipidemikler
• gözlemsel çalışma
• ilaç-ilaç etkileşimleri
• serbest eczane

DETECTING DRUG-DRUG INTERACTIONS INDUCED BY ANTI-HYPERLIPIDEMICS: AN OBSERVATIONAL STUDY

Öz

Objective: This study aimed to reveal drug-drug interactions (DDIs) due to antihyperlipidemic drugs through programs used to detect DDIs. Material and Method: 250 prescriptions containing at least one anti-hyperlipidemic drug and a drug from a different pharmacological group were evaluated in terms of DDIs between November 2022 and April 2023. Evaluations were performed using three different DDI checking programs (RxMediaPharma®, Medscape, and Drugs.com) on prescriptions filled by a community pharmacy in Van. Result and Discussion: Anti-hyperlipidemic drug-induced DDIs were detected in 115 of the prescriptions. DDIs occurred between 38 active ingredient pairs. It was determined that 85% of the interactions were caused by atorvastatin. The most common DDI was found between atorvastatin and pantoprazole. For only 7 of the 38 different ingredient pairs, all three programs yielded a result indicating an interaction. DDIs induced by anti-hyperlipidemic drugs were generally found to be at moderate levels. However, it is seen that the three DDI checking programs used in the study provide different results in detecting DDIs.

Anahtar Kelimeler

• Antihyperlipidemics
• community pharmacy
• drug-drug interactions
• observational study

Destekleyen Kurum

None

Etik Beyan

This study was conducted after Van Yüzüncü Yıl University Non-interventional Research Ethics Committee approved the study ethically (Date:18/11/2022, Decision No: 2022/11-30).

Teşekkür

This study was created by expanding the graduation project that the first author completed at Van Yüzüncü Yıl University Faculty of Pharmacy under the supervision of the corresponding author, and the shortest version of this study was presented at ISOPS-14. The authors would like to thank the corresponding community pharmacy for providing data.

Kaynakça

1. 1. Berberich, A.J., Hegele, R.A. (2022). A modern approach to dyslipidemia. Endocrine Reviews, 43(4), 611-53. [CrossRef]
2. 2. Ferraro, R.A., Leucker, T., Martin, S.S., Banach, M., Jones, S.R., Toth, P.P. (2022). Contemporary management of dyslipidemia. Drugs, 82(5), 559-76.
3. 3. International Pharmaceutical Federation (2022). Cardiovascular diseases: A handbook for pharmacists. Retrieved September 01, 2024, from https://ncd.fip.org/publications/cardiovascular-diseases-a-handbook-for-pharmacists/. Accessed date: 01.10.2025.
4. 4. Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M.J., Backer, G. D., Delgado, V., Ference, B.A., Graham, I. M, Halliday, A., Landmesser, U., Mihaylova, B., Pedersen, T. R., Riccardi, G., Richter, D. J., Sabtine, M. S., Taskinen, M., Tokgozoglu, L., Wiklund, O. (2020). 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Russian Journal of Cardiology, 25(5), 3826. [CrossRef]
5. 5. Poli, A., Barbagallo, C.M., Cicero, A.F.G., Corsini, A., Manzato, E., Trimarco, B., Bernini, F., Visioli, F., Banch,, A., Canzone, G., Crescini, C., Kreutzenberg, S., Ferrar, N., Gambacciani, M., Ghiselli, A., Lubrano, C., Marelli, G., Marrocco, W., Montemurro, V., Parretti, D., Pedretti, R., Perticone, F., Stella, R., Marangoni, F. (2018). Nutraceuticals and functional foods for the control of plasma cholesterol level. An intersociety position paper. Pharmacological Research, 134, 51-60. [CrossRef]
6. 6. Türkiye Endokrinoloji ve Metabolizma Derneği (2021). Dislipidemi Tanı Ve Tedavi Kılavuzu, Retrieved September 01, 2023, from https://file.temd.org.tr/Uploads/publications/guides/documents/20211026164 3012021tbl_kilavuzb66456ad2f.pdf. Accessed date: 01.10.2025.
7. 7. Wiggins, B.S., Saseen, J.J., Pagell, R.L. Reed, B.N., Sneed, K., Kostis, J.B., Lanfear, D., Virani, S., Morris, P.B. (2016). Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: A scientific statement from the American Heart Association. Circulation, 134, 468-495. [CrossRef]
8. 8. Li, S., Yu, Y., Jin, Z., Dai, Y., Lin, H., Jiao, Z., Ma, G., Cai, W., Han, B., Xiang, X. (2019). Prediction of pharmacokinetic drug-drug interactions causing atorvastatin-induced rhabdomyolysis using physiologically based pharmacokinetic modelling. Biomedicine & Pharmacotherapy, 119, 109416.

9. 9. Kayaalp, O. (2009). Rasyonel Tedavi Yönünden Tıbbi Farmakoloji, 12. Baskı. Pelikan Yayıncılık, Ankara.
10. 10. Aktay, G., Hancı, H.İ, Balseven, A. (2003). İlaç Etkileşimleri ve Hekim Sorumluluğu. Sürekli Tıp Eğitimi Dergisi, 12(7), 261-264.
11. 11. Özkaya, Y., Özçeli̇kay, G. (2025). Yaşlılarda akılcı ilaç kullanımında eczacı sorumluluğu. Ankara Üniversitesi Eczacilik Fakültesi Dergisi, 49(1), 109-118. [CrossRef]
12. 12. Lalatović, N., Pantović, S., Nedović-Vuković, M., Kostić, M. (2023). Risk factors for potential drug-drug interactions in outpatients with dyslipidemia. Iranian Journal of Public Health, 52(7), 1466 [CrossRef]
13. 13. Demirpolat, E., Güneş, N. (2025). Comparison and analysis of 4 drug interaction databases in nephrology patients using clinical pharmacy approaches: A cross-sectional study. İstanbul Journal of Pharmacy, 55(1), 1-9. [CrossRef]
14. 14. Sancar, M., Kaşık, A., Okuyan, B., Batuhan, S., İzzettin, F. V. (2019). Determination of potential drug-drug interactions by using various software programs at community pharmacy setting. Turkish Journal of Pharmaceutical Sciences, 16(1), 14-19. [CrossRef]
15. 15. Donner, A., Eliasziw, M. (1992). A goodness-of-fit approach to inference procedures for the kappa statistic: Confidence interval construction, significance-testing and sample size estimation. Statistics in Medicine, 11(11), 1511-1519. [CrossRef]
16. 16. Landis, J. R., Koch, G. G. (1977). The measurement of observer agreement for categorical data. Biometrics, 33(1), 159-174.
17. 17. Morival, C., Westerlynck, R., Bouzillé, G., Cuggia, M., Le Corre, P. (2018). Prevalence and nature of statin drug-drug interactions in a university hospital by electronic health record mining. European journal of Clinical Pharmacology, 74(4), 525-534. [CrossRef]
18. 18. Barkas, F., Elisaf, M., Rizos, C. V., Klouras, E., Kostapanos, M. S., Liberopoulos, E. (2015). Proton pump inhibitors and statins: A possible interaction that favors low-density lipoprotein cholesterol reduction?. Hippokratia, 19(4), 332. [CrossRef]
19. 19. Aykut, B., Arslan, M. (2023). An observational study on drug interactions caused by proton pump inhibitors. European Journal of Life Sciences, 2(1), 25-30. [CrossRef]
20. 20. Biswas, K., Tiwari, A., Jadhav, P., Goel, A., Chanukya, G.V. (2021). Rosuvastatin and fenofibrate combination in the treatment of mixed hyperlipidemia: A narrative review. Journal of Current Medical Research and Opinion, 4(03), 867-877. [CrossRef]
21. 21. Farnier, M., Vrablik, M., & Catapano, A. L. (2023). Is there still a place for fenofibrate-statin combination therapy? Fenofibrate-statin combination therapy. European Atherosclerosis Journal, 2(3), 44-49. [CrossRef]
22. 22. Ferreira, S.P.S., Hall, R.P., Majumdar, M., Goudot, G., Jessula, S., Bellomo, T. Lee, I., Kukreja, N., Parmar, G., Boada, A. E., Dua, A. (2023). Atorvastatin effect on clopidogrel efficacy in patients with peripheral artery disease. Annals of Vascular Surgery, 95, 74-79. [CrossRef]
23. 23. Günay, A., Demirpolat, E., Ünal, A., Aycan, M. B. (2022). A comparison of four drug-drug interaction databases for patients undergoing haematopoietic stem cell transplantation. Journal of Clinical Pharmacy and Therapeutics, 47(10), 1711-1719. [CrossRef]